Combined therapy in vulvar lichen sclerosus: does topical tretinoin improve the efficacy of mometasone furoate?

J Dermatolog Treat

a Dipartimento di Scienze Mediche, Sezione di Dermatologia e Malattie Infettive , Università degli Studi di Ferrara, Ferrara, Italy.

Published: September 2017

Unlabelled: Abstrract Purpose: To assess efficacy and safety profile of combining a potent corticosteroid with a retinoid in the treatment of vulvar lichen sclerosus (VLS).

Methods: We retrospectively compared 21 VLS patients treated with tretinoin (T) in short-contact therapy and mometasone furoate (MMF) (group A) and 20 treated with cold cream (CC) and MMF (group B) for 5 consecutive days/week for 12 weeks. The efficacy parameters were the response rate, the percentage of patients achieving an improvement from baseline of ≥75% in subjective and objective scores and the mean reduction in subjective and objective scores.

Results: Thirteen patients (75.2%) were considered as responders in group A and 15 (78.9%) in group B; 50% and 61.1% of patients in group A and 100% and 63.1% in group B achieved an improvement of at least 75% in subjective and objective scores, respectively. The scheme combining MMF and CC was better tolerated than the combination of MMF and T.

Conclusions: The combination with a topical retinoid did not enhance the effectiveness of a potent corticosteroid in the treatment of VLS. Either the scarce efficacy of the short-contact therapy regimen or a less favorable safety profile of such combination may account for these findings.

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2016.1277178DOI Listing

Publication Analysis

Top Keywords

subjective objective
12
vulvar lichen
8
lichen sclerosus
8
safety profile
8
potent corticosteroid
8
short-contact therapy
8
mmf group
8
objective scores
8
group
6
combined therapy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!